ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Comparative Outcomes of Tricuspid-Dedicated Versus Non-Dedicated Devices in Transcatheter Tricuspid Edge-to-Edge Repair.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Transcatheter tricuspid edge-to-edge repair (T-TEER) has expanded treatment options for tricuspid regurgitation (TR). The procedure was initially performed using systems designed for mitral valve repair, which were replaced by tricuspid-dedicated devices. This retrospective study compared outcomes of tricuspid-dedicated devices (TriClip or PASCAL) with a non-dedicated device (MitraClip) used for TR treatment. MATERIAL AND METHODS We analyzed data from 44 consecutive patients (mean age 74.7±7.5 years) who underwent T-TEER (2018-2024): 22 with non-dedicated (MitraClip) and 22 with dedicated systems (TriClip or PASCAL). The primary endpoint was technical success. Secondary endpoints included post-procedural TR≤ moderate, ≥2-grade TR reduction, peri-procedural complications, and 6-month mortality. RESULTS Baseline characteristics were largely balanced, although the non-dedicated group showed greater left-ventricular dysfunction. Technical success was significantly higher with dedicated systems (100% vs 77.3%, risk ratio 1.29; 95% CI 1.03-1.63; P=0.048) Post-procedural moderate or less TR and a reduction of ≥2 grades was achieved in 68.2% of patients with dedicated devices vs 31.8% with non-dedicated devices (risk ratio 2.14, 95% CI 1.09-4.21; P=0.02). Mortality during a 6-month follow-up was comparable between both cohorts (0.0% vs 9.1%; risk ratio 1.10; 95% CI 0.96-1.26; P=0.23). CONCLUSIONS Tricuspid-dedicated systems (TriClip or PASCAL) were associated with higher procedural success rates and greater TR reduction. They improved early outcomes and enabled the application of T‑TEER in a broader population of patients with less-advanced heart failure. Given the limited sample size and retrospective design, these findings should be interpreted with caution and regarded as exploratory and hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.